Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.
The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.
This agreement produced a license for a UHN technology on April 17, 2013.
CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor
Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.
The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto. (more…)